<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00132639</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG 0204-MF</org_study_id>
    <secondary_id>C000000032</secondary_id>
    <nct_id>NCT00132639</nct_id>
  </id_info>
  <brief_title>Study of Preoperative Docetaxel or Cisplatin (CDDP) + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Randomized Phase II Study of the Induction Chemotherapy With Docetaxel Alone vs CDDP + Docetaxel for C-stage IB-II Non-Small Cell Lung Cancer (JCOG 0204-MF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haruhiko Fukuda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the preoperative
      docetaxel and docetaxel-cisplatin combination in c-stage IB/II NSCLC, and select the optimal
      preoperative therapy for phase III trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperative chemotherapy has substantial theoretical advantage. Several controlled trials
      are under way in early stage (clinical stage IB-II) nonsmall cell lung cancer (NSCLC). In
      each trial, platinum-based doublet chemotherapy is employed. Although platinum-based doublet
      is the treatment of choice for advanced NSCLC, risk/benefit balance might well be different
      in earlier stages. There have been no prospective randomized trials to choose an optimal
      preoperative chemotherapy in early stage NSCLC.

      Comparison: Preoperative cisplatin-docetaxel combination versus docetaxel monotherapy in
      clinical stage IB/II NSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival rate at 1 year</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment compliance</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate to chemotherapy</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response (CR) rate</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete resection rate</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-surgical morbidity/mortality</measure>
    <time_frame>during the study conduct</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pulmonary Neoplasms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preoperative docetaxel-cisplatin combination chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative docetaxel monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preoperative docetaxel-cisplatin combination chemotherapy</intervention_name>
    <description>Preoperative docetaxel-cisplatin combination chemotherapy</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preoperative docetaxel monotherapy</intervention_name>
    <description>Preoperative docetaxel monotherapy</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed, pathologically documented NSCLC

          -  Clinical stages IB (T2N0M0), IIA (T1N1M0) or IIB (T2N1M0 or T3N0M0)

          -  Ages: 15-74 years old

          -  ECOG performance status 0 or 1

          -  Measurable disease

          -  Ample organ function

          -  Signed informed consent

        Exclusion Criteria:

          -  Invasion to the first rib or more superior chest wall

          -  Metastasis to, or involvement of, mediastinal node

          -  Active concomitant malignancy

          -  Unstable angina, recent myocardial infarction, or heart failure

          -  Uncontrolled diabetes or hypertension

          -  Pregnant or lactating women

          -  Other severe complications

          -  Systemic use of corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harubumi Kato, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tokyo Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Chuo-ku,Tsukiji,5-1-1</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2005</study_first_submitted>
  <study_first_submitted_qc>August 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2005</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Japan Clinical Oncology Group</investigator_affiliation>
    <investigator_full_name>Haruhiko Fukuda</investigator_full_name>
    <investigator_title>JCOG Data Center</investigator_title>
  </responsible_party>
  <keyword>pulmonary neoplasm</keyword>
  <keyword>preoperative chemotherapy</keyword>
  <keyword>cisplatin, docetaxel</keyword>
  <keyword>randomized trial</keyword>
  <keyword>clinical stage IB or II nonsmall cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

